Urokinase-type plasminogen activator breast cancer

F6. Foekens, J. S., Schmitt, M., van Putten, W., Peters, H. A., Bontenbal, M., Janicke, F., and Klijn, J., Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52, 6101-6105 (1992). 

G5. Grondahl-Hansen, J., Christensen, 1., Rosenquist, C., Brunner, N., Mouridsen, H. T., Dano, K., and Blichert-Toft, M., High levels of urokinase-type plasminogen activator and its inhibitor PA1-I in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53, 2513-2521 (1993). 

Jl. Janicke, F., Schmitt, M., Hafter, R., Holrieder, A., Babic, R., Ulm, K., Gossner, W., and Graeff, H., Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4, 69-78 (1990). 

Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987 47 4043 4046. 

Harbeck N, Alt U, Berger U et al (2001) Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7 2757-2764... 

Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002 3 ... 

Janicke F, Prechtl A, Thomssen C. Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001 93 913-20. 

Harbeck N, Kates RE, Look MR et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 2002 62 4617 622. 

Look MR van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAl-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002 94 116-128. 

D2. Dazzi, C., Cariello, A., Maioli, P., et al., A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. Cancer Invest. 21, 208-216 (2003). 

Cl. Castello, R., Estelles, A., Vazquez, C., et al.. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin. Chem. 48, 1288-1295 (2002). 

Sweep, C. G. J., Geurts-Moespot, J., Grebenschikov, N., et al.. External quality assessment of trans-european multicenter antigen determination (enzyme-linked immunosorbent assay) or urokinase plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer extracts. Br. J. Cancer 78, 1434-1441 (1998). 

---